Fact-checked by Grok 2 weeks ago

Erectile dysfunction

Erectile dysfunction (ED), also known as impotence, is the recurrent inability to achieve or maintain a penile erection sufficient for satisfactory sexual performance.^[1] It is a common condition that can significantly impact quality of life, self-esteem, and relationships.^[2] ED affects a substantial portion of the male population, with prevalence increasing with age; approximately 52% of men aged 40 to 70 in the United States experience some degree of ED, and global estimates project around 322 million men worldwide will be affected by 2025.^[2]^[3] The condition often stems from a combination of physical, psychological, and lifestyle factors, including cardiovascular disease, diabetes, obesity, hypertension, low testosterone levels, smoking, excessive alcohol use, stress, anxiety, and depression.^[1]^[2] Risk factors such as aging, certain medications, prostate cancer treatments, and neurological disorders further contribute to its development.^[1] Diagnosis typically involves a medical history, physical examination, blood and urine tests to identify underlying conditions, ultrasound to assess penile blood flow, and psychological evaluation if needed.^[4] Treatment is multifaceted and tailored to the cause, beginning with lifestyle changes like weight loss, exercise, quitting smoking, and reducing alcohol intake, which can improve symptoms in many cases.^[4] Pharmacological options include oral phosphodiesterase-5 inhibitors such as sildenafil (Viagra), tadalafil (Cialis), vardenafil (Levitra), and avanafil (Stendra), which enhance blood flow to the penis; other approaches encompass self-injections of alprostadil, intraurethral suppositories, testosterone replacement therapy for hormonal deficiencies, vacuum erection devices, and counseling for psychological components.^[4] For severe or refractory cases, surgical interventions like penile implants may be considered.^[4] Early intervention is crucial, as ED can signal broader health issues like heart disease or diabetes.^[2]

Definition and Epidemiology

Definition

Erectile dysfunction (ED), also known as impotence, is defined as the persistent inability to achieve or maintain a penile erection sufficient for satisfactory sexual performance. According to the DSM-5 criteria, this involves marked difficulty in obtaining or sustaining an erection during at least 75% of sexual activities, persisting for a minimum of six months, causing clinically significant distress or interpersonal difficulty, and not attributable solely to substances, another medical condition, or a relational factor.^[5] The ICD-11 classifies it as male erectile dysfunction (HA01.1), characterized by an inability or marked reduction in the ability to attain or sustain a penile erection of sufficient duration and rigidity for satisfactory sexual activity, occurring on almost all or all (approximately 75% or more) occasions of sexual activity without the influence of medication or other substances.^[6] This condition affects a substantial number of men globally, with prevalence rising with age.^[2] ED must be distinguished from occasional erectile difficulties, which are common and often transient, arising from factors such as stress, fatigue, or alcohol use, and do not meet diagnostic thresholds for persistence or impairment.^[7] It differs from priapism, a medical emergency involving a prolonged, painful erection lasting more than four hours without sexual stimulation, resulting from failure of detumescence mechanisms.^[8] Similarly, ED is not synonymous with Peyronie's disease, which features penile curvature and deformity due to fibrous plaque formation in the tunica albuginea, potentially hindering sexual function but defined by structural changes rather than erectile failure per se.^[9] At its core, an erection is a hemodynamic event driven by increased arterial blood flow into the corpora cavernosa—two sponge-like chambers in the penis—following smooth muscle relaxation triggered by sexual stimulation, coupled with restricted venous outflow that traps blood to maintain rigidity.^[2] In ED, this process is disrupted, leading to inadequate penile tumescence despite arousal.^[2]

Prevalence and Risk Factors

Erectile dysfunction (ED) affects a substantial portion of men worldwide, with prevalence estimates varying by age and methodology. A landmark population-based study, the Massachusetts Male Aging Study (MMAS), conducted between 1987 and 1989 on men aged 40 to 70 years, reported a combined prevalence of minimal, moderate, and complete ED at 52%, with complete ED increasing from 5% in the 40-49 age group to 15% in those aged 70 and older.^[10] Global estimates project that approximately 322 million men will be affected worldwide by 2025, up from 152 million in 1995, based on 1999 extrapolations, driven by aging populations and increasing chronic disease burdens. As of 2025, updated global epidemiological data remains limited, with calls for new studies to assess current prevalence.^[11]^[12] A systematic review of international studies estimated overall ED prevalence at 3% to 76.5%, with rates consistently higher in older age groups.^[13] Demographic variations highlight elevated risks in specific populations. Prevalence increases markedly with age, affecting up to 50% of men over 50 and rising further in those over 70.^[2] Among men with comorbidities, rates are particularly high; for instance, ED occurs in 50% to 75% of individuals with type 2 diabetes mellitus, with nearly 80% of adult diabetic men experiencing some degree of dysfunction in recent cohort studies.^[14] Ethnic differences also play a role, with higher reported rates in certain groups, such as non-Hispanic Black and Hispanic men compared to non-Hispanic White men in U.S.-based epidemiological data, though global variations underscore the influence of socioeconomic and access-to-care factors.^[15] Key modifiable and non-modifiable risk factors contribute significantly to ED incidence. Age is the strongest non-modifiable factor, with odds ratios (OR) for ED increasing progressively (e.g., OR 2.0-4.0 for men over 60 compared to those under 40).^[16] Among modifiable risks, diabetes confers an OR of approximately 3.0-4.0, while smoking is associated with an OR of 1.5-2.5, and obesity yields an OR of 1.5-3.0, based on prospective cohort analyses.^[17]^[18] Other cardiovascular risks, including hypertension (OR 1.5-2.0) and hyperlipidemia (OR 1.2-1.8), further elevate susceptibility, often clustering in metabolic syndrome.^[19] Emerging risks post-2020 include long-term effects of COVID-19 and exacerbated mental health disorders. ED reported in 15-25% of long-COVID cases up to 2 years post-infection (e.g., vascular/endothelial damage; based on cohort studies, with ongoing research on causality).^[20] Additionally, the pandemic has amplified psychological contributors, with depression and anxiety—prevalent in 20-30% of post-2020 cohorts—associated with an increased ED risk (odds ratio approximately 1.4) due to stress-related neuroendocrine disruptions.^[21]^[22]

Clinical Presentation

Physical Signs and Symptoms

Erectile dysfunction (ED) is primarily characterized by the consistent or recurrent inability to achieve or maintain a penile erection sufficient for satisfactory sexual performance.^[23] This core physical manifestation often presents as difficulty in attaining penile rigidity during sexual activity or an inability to sustain the erection long enough for intercourse.^[2] Associated physical signs may include a reduction or absence of spontaneous morning or nocturnal erections, which are typically present in healthy males and can help differentiate organic from psychogenic causes when preserved.^[2] In cases comorbid with conditions like Peyronie's disease, involving penile fibrosis and plaque formation, patients may experience penile curvature during attempted erections or pain associated with the erection process.^[9]^[24] The severity of ED is commonly graded using the International Index of Erectile Function (IIEF), a validated questionnaire that assesses erectile function through scores on the erectile function domain; mild ED corresponds to scores of 22-25, mild to moderate to 17-21, moderate to 11-16, and severe to 1-10.^[25] For a formal diagnosis, symptoms must persist for at least 3 months to distinguish transient issues from chronic dysfunction.^[26]

Psychological Impact

Erectile dysfunction (ED) often leads to significant psychological distress, including heightened anxiety, depression, and diminished self-esteem among affected individuals. Studies indicate that depression affects approximately 65% of men with ED, while anxiety impacts around 38%, with both conditions co-occurring in about 32% of cases.^[27] These mental health challenges are exacerbated by the condition's impact on sexual performance, fostering feelings of inadequacy and reduced self-worth, particularly in younger men who may perceive ED as a profound threat to their masculinity.^[28]^[29] Furthermore, the experience of ED triples the risk of developing depression compared to men without the condition.^[28] The psychological toll extends to interpersonal relationships, where ED contributes to decreased sexual satisfaction for both partners and increased emotional strain. Partners frequently report feelings of rejection, unattractiveness, and lowered quality of life, with up to 74% of female partners viewing ED as a significant relational issue.^[29] This can manifest as partner distress, guilt on the part of the affected individual, and overall relational tension, potentially leading to reduced intimacy and communication breakdowns.^[28] In severe cases, such dynamics may contribute to broader conflicts, including frustration and emotional withdrawal within the couple.^[30] A common pattern is the cycle of psychogenic exacerbation, where performance anxiety triggered by prior episodes of ED impairs subsequent arousal, creating a self-perpetuating loop of fear and dysfunction.^[28] This vicious cycle often involves heightened sympathetic nervous system activity, which distracts from sexual focus and worsens erectile difficulties, further eroding confidence.^[30] Over time, these effects can lead to long-term avoidance of intimate situations and persistent body image issues tied to male sexual identity, resulting in sustained declines in psychological and social well-being.^[29] Such chronic impacts highlight ED's role in broader emotional isolation and emasculation feelings lasting years after onset.^[28]

Etiology

Physical Causes

Physical causes of erectile dysfunction (ED) encompass organic factors that impair the vascular, neurological, hormonal, anatomical, or structural integrity necessary for achieving and maintaining an erection. These etiologies account for the vast majority of ED cases, with vascular disorders being the predominant contributor.^[2] Vascular causes involve disruptions in blood flow to the penis, primarily due to atherosclerosis and endothelial dysfunction. Atherosclerosis narrows the penile arteries, reducing inflow and leading to insufficient rigidity during arousal; this condition often precedes coronary artery disease by several years, affecting nearly 50% of men with existing cardiovascular issues.^[2] Endothelial dysfunction, characterized by impaired nitric oxide production and vasodilation, further exacerbates reduced penile blood flow and is a shared mechanism with systemic cardiovascular disease.^[2] Vascular etiologies are implicated in the majority of organic ED cases.^[2] Neurological causes stem from damage to the nerves controlling erectile function, such as peripheral neuropathy often associated with diabetes mellitus—a key risk factor for ED.^[1] Spinal cord injuries disrupt central neural pathways, while conditions like multiple sclerosis impair signal transmission from the brain to the penis, resulting in inconsistent or absent erections.^[2] Hormonal causes include imbalances that affect libido and erectile capability, notably hypogonadism with low testosterone levels below 300 ng/dL, which occurs in up to 35% of men with ED.^[2] Thyroid disorders, present in about 6% of ED cases, can similarly alter hormonal regulation and vascular responsiveness.^[2] Anatomical and structural causes involve direct alterations to penile tissue or supporting structures. Penile fibrosis leads to scarring that limits tissue expansion during engorgement, while post-prostatectomy damage from radical surgery affects cavernous nerves and vessels, causing ED in approximately 85% of patients.^[2] Peyronie's disease, characterized by fibrous plaques in the tunica albuginea, induces penile curvature and pain; the condition affects approximately 3–9% of adult men.^[31] Iatrogenic causes arise from medical interventions or treatments. Certain medications, including antihypertensives and antidepressants, contribute to ED in about 25% of cases by interfering with neural or vascular mechanisms.^[2] Radiation therapy for prostate cancer damages pelvic nerves and endothelium, resulting in ED rates of around 25-50% post-treatment.^[2]

Psychological and Lifestyle Causes

While causes of erectile dysfunction (ED) can be categorized, many cases involve a combination of organic and psychogenic factors.^[32] ED can arise from purely psychological origins in a minority of cases, particularly among younger men, where sudden onset and preserved nocturnal erections are common indicators.^[33] Depression significantly contributes to ED, with affected men facing nearly a five-fold higher prevalence of the condition, while ED itself elevates depression risk over three-fold based on longitudinal meta-analyses.^[33] Anxiety disorders, including generalized anxiety, exacerbate ED by heightening sympathetic nervous system activity and disrupting arousal pathways.^[2] Performance anxiety, characterized by self-monitoring and fear of failure during sexual activity, often initiates a cycle of avoidance and worsening dysfunction in otherwise healthy individuals.^[33] Chronic stress from work demands or interpersonal conflicts inhibits sexual arousal by elevating cortisol levels and promoting emotional distraction, leading to inhibited genital response.^[2] Relationship conflicts, such as unresolved tensions or mismatched sexual expectations, further contribute by fostering emotional distance and reduced intimacy, which can manifest as arousal difficulties.^[2] Lifestyle factors play a prominent role in ED etiology. Excessive alcohol consumption, defined as more than 14 drinks per week, damages endothelial function and peripheral nerves, increasing ED risk through chronic toxicity.^[2] Illicit drug use, particularly cocaine, impairs vascular and neural mechanisms essential for erection, contributing to up to 25% of medication- or substance-related ED cases.^[2] Sedentary behavior, such as prolonged sitting or minimal physical activity, correlates with higher ED incidence by promoting endothelial dysfunction and reduced cardiovascular health.^[34] Poor sleep quality or duration below six hours nightly disrupts testosterone production and heightens oxidative stress, thereby elevating ED susceptibility.^[35] Behavioral patterns like overuse of pornography can lead to desensitization and mismatched expectations, associating with problematic consumption patterns that impair real-life sexual responsiveness in some men.^[36]

Pathophysiology

Normal Erectile Physiology

Erection begins with neural initiation triggered by sexual stimulation, which activates the parasympathetic nervous system from the sacral spinal cord segments S2-S4. This stimulation leads to the release of nitric oxide (NO) from non-adrenergic, non-cholinergic nerve endings in the cavernous nerves, acting as the primary neurotransmitter for penile erection. NO diffuses into the smooth muscle cells of the corpora cavernosa, where it activates guanylate cyclase to increase cyclic guanosine monophosphate (cGMP) levels, resulting in reduced intracellular calcium and subsequent relaxation of the smooth muscle.^[37] The vascular process follows, characterized by relaxation of the trabecular smooth muscle in the corpora cavernosa and helicine arteries, which dramatically increases arterial blood inflow—up to 20- to 40-fold during erection. This influx expands the sinusoidal spaces within the corpora cavernosa, leading to tumescence and compression of the subtunical venular plexuses against the rigid tunica albuginea, which restricts venous outflow and traps blood to achieve rigidity. Full erection is maintained as intracavernosal pressure rises to approximately 100 mmHg, supported by rhythmic contractions of the ischiocavernosus and bulbospongiosus muscles.^[37]^[38] Testosterone plays a permissive hormonal role in erectile physiology, maintaining libido and enhancing the responsiveness of penile tissues to neural and vascular signals, with circulating levels below approximately 200-300 ng/dL potentially impairing erectile function despite intact neural pathways. Although not directly initiating erection, testosterone supports the structural integrity of cavernosal smooth muscle and endothelial cells, facilitating NO production and overall erectile capacity.^[38]^[39] The physiological phases of erection transition from the flaccid state, where tonic sympathetic tone maintains smooth muscle contraction and low blood flow (PO2 ~35 mmHg), to tumescence with initial arterial dilation and sinusoidal filling. Full erection ensues with maximal rigidity and elevated intracavernosal pressure (PO2 ~90 mmHg), followed by detumescence upon cessation of stimulation, where sympathetic activation via norepinephrine release contracts the smooth muscle, reopens venous channels, and rapidly restores the flaccid state in a triphasic process: transient pressure surge, slow emptying, and fast outflow restoration.^[37]^[38]

Pathological Mechanisms

Erectile dysfunction arises from disruptions in the intricate processes governing penile erection, primarily involving vascular, neural, endothelial, fibrotic, and hormonal elements that impair the relaxation of cavernosal smooth muscle and subsequent blood inflow. In the normal erectile physiology, nitric oxide (NO) released from nerve endings and endothelial cells activates soluble guanylate cyclase to elevate cyclic guanosine monophosphate (cGMP) levels, promoting smooth muscle relaxation.^[40] Vascular pathology in erectile dysfunction often stems from impairment in the NO-cGMP signaling pathway, where reduced NO bioavailability leads to diminished cGMP production and persistent contraction of penile smooth muscle cells. This disruption results in insufficient cGMP to overcome the normal activity of phosphodiesterase type 5 (PDE5), the enzyme responsible for cGMP degradation, thereby preventing adequate vasodilation and penile tumescence.^[41]^[40] Neurological disruption contributes to erectile dysfunction by damaging the pudendal nerve or central neural pathways, which reduces the transmission of parasympathetic signals essential for initiating NO release and smooth muscle relaxation in the corpora cavernosa. Such interruptions impair the neural coordination required for erectile response, leading to inadequate penile rigidity.^[42]^[43] Endothelial dysfunction plays a central role in the pathogenesis of erectile dysfunction, characterized by oxidative stress and chronic inflammation that diminish endothelial nitric oxide synthase (eNOS) activity, thereby reducing NO-mediated vasodilation. This process is closely linked to systemic atherosclerosis, where reactive oxygen species (ROS) scavenge NO, exacerbating vascular resistance and limiting penile blood flow.^[44]^[40] Fibrotic changes in the penis manifest as excessive collagen deposition within the tunica albuginea and corpora cavernosa, altering the structural compliance necessary for sinusoidal expansion during erection. This fibrosis, driven by transforming growth factor-beta (TGF-β) signaling and hypoxia-induced remodeling, replaces elastic fibers with rigid scar tissue, restricting penile engorgement and contributing to venous leakage.^[45]^[40] Hormonal imbalances, particularly in aging or disease states, lead to androgen receptor insensitivity or reduced testosterone signaling, which downregulates eNOS expression and impairs NO production in penile tissues. This results in diminished smooth muscle relaxation and vascular responsiveness, exacerbating erectile dysfunction through altered cellular maintenance and inflammatory pathways.^[46]^[47]

Diagnosis

Medical History and Physical Examination

The diagnosis of erectile dysfunction (ED) begins with a comprehensive medical history to evaluate the patient's symptoms, risk factors, and potential underlying causes. Clinicians should assess the onset, frequency, and severity of ED, distinguishing between sudden onset—which may suggest psychogenic factors or acute vascular events—and gradual progression, indicative of chronic conditions such as cardiovascular disease or diabetes.^[2]^[48] Validated questionnaires like the International Index of Erectile Function (IIEF), a 15-item self-report tool scoring erectile function, intercourse satisfaction, orgasmic function, sexual desire, and overall satisfaction, are recommended to quantify severity and track changes over time.^[48] A detailed sexual history is essential, including inquiries about erection rigidity and duration, presence of morning or nocturnal erections, libido, ejaculation, orgasm, and performance with masturbation versus intercourse, as well as partner-related dynamics.^[2] The medical history should screen for comorbidities such as hypertension, diabetes, hyperlipidemia, peripheral vascular disease, neurological disorders, and endocrine conditions, alongside lifestyle factors like smoking, alcohol use, and obesity.^[48]^[2] Medication review is critical to identify potential contributors, including antihypertensives (e.g., beta-blockers), antidepressants, antipsychotics, and hormonal therapies.^[48] Psychosocial elements, such as stress, depression, or relationship issues, should also be explored to differentiate psychogenic from organic ED.^[2] For differential diagnosis, targeted questions help rule out hypogonadism by assessing symptoms like reduced libido, fatigue, and absence of morning erections, often prompting further testosterone evaluation.^[48]^[2] Prostate-related issues, such as benign prostatic hyperplasia (BPH) or lower urinary tract symptoms (LUTS), are screened through queries about urinary function and prior prostate interventions.^[48] The physical examination focuses on identifying anatomical or systemic abnormalities contributing to ED. Genital inspection evaluates penile curvature, plaques (suggesting Peyronie's disease), fibrosis, phimosis, testicular size and consistency (for hypogonadism), and signs of infection or trauma.^[48]^[2] Vascular assessment includes palpation of femoral and pedal pulses to detect peripheral artery disease, along with blood pressure measurement.^[48] Neurological testing encompasses perineal sensation, anal sphincter tone, bulbocavernosus reflex (to evaluate sacral nerve integrity), and cremasteric reflex (for thoracolumbar pathway function).^[2] Additional checks for secondary sexual characteristics, such as body hair distribution and gynecomastia, aid in identifying endocrine disorders.^[48] Red flags like absent pulses or abnormal reflexes warrant prompt investigation for underlying vascular or neurological pathology.^[2]

Laboratory and Imaging Tests

Laboratory testing in the diagnosis of erectile dysfunction (ED) typically includes blood work to identify underlying systemic conditions that may contribute to the disorder. Morning serum total testosterone levels are recommended for all men presenting with ED, with levels below 300 ng/dL indicating potential testosterone deficiency.^[32] Additional selective tests, guided by clinical history, may encompass fasting blood glucose or HbA1c to screen for diabetes, a lipid profile to assess cardiovascular risk, prostate-specific antigen (PSA) for prostate evaluation in appropriate age groups, and thyroid function tests if symptoms suggest hypothyroidism.^[32] These tests help establish objective data on hormonal, metabolic, and cardiovascular factors influencing erectile function. Penile Doppler ultrasonography, often performed after intracavernosal injection of a vasodilator, serves as the gold standard for evaluating vascular causes of ED by assessing arterial inflow and venous outflow. Key parameters include peak systolic velocity (PSV), where values below 25-30 cm/s suggest arterial insufficiency, and end-diastolic velocity (EDV), with elevations above 3-5 cm/s indicating veno-occlusive dysfunction; a resistance index greater than 0.8 is considered normal.^[32] This non-invasive imaging modality provides direct visualization of penile blood flow and is particularly useful when history and physical examination point to vasculogenic etiology. Nocturnal penile tumescence (NPT) testing, including rigidity monitoring with devices such as the RigiScan, measures erectile events during sleep to differentiate psychogenic from organic ED. Adequate rigidity is defined as at least 60% at the penile tip for a minimum of 10 minutes across multiple nights, with reduced or absent erections supporting an organic cause, though the test is prone to false negatives due to factors like sleep disorders.^[32] In select cases, magnetic resonance imaging (MRI) may be employed to investigate neurological or structural abnormalities contributing to ED, such as in posttraumatic scenarios or suspected Peyronie's disease with fibrosis. MRI can delineate penile anatomy, including cavernosal structures and potential venous leakage, but it is not routinely recommended due to limited availability and cost.^[49] Specialized vascular assessments, such as intracavernosal injection (ICI) of agents like prostaglandin E1, evaluate erectile response directly; a rigid erection achieved within 10 minutes and sustained for up to 30 minutes indicates intact vascular mechanisms, often combined with Doppler ultrasound for enhanced diagnostic accuracy.^[32] Rigidity monitoring devices complement NPT by quantifying erection firmness, while more invasive options like cavernosometry (where the ability to maintain intracavernosal pressure of 90-150 mm Hg with an infusion rate of <20 mL/min indicates normal function) or selective internal pudendal arteriography are reserved for rare cases, such as trauma-related ED or candidates for revascularization.^[32]

Management and Treatment

Lifestyle Modifications and Prevention

Lifestyle modifications play a crucial role in managing and preventing erectile dysfunction (ED), particularly by addressing modifiable risk factors such as obesity, inactivity, and smoking, which contribute to vascular and metabolic impairments. Evidence from randomized controlled trials indicates that these interventions can improve erectile function, with benefits often seen within months of adoption. For instance, comprehensive lifestyle changes targeting weight, exercise, and diet have restored normal erectile function in a significant proportion of affected men.^[50]^[51] Weight loss is a key intervention for obese men with ED, as excess body weight exacerbates endothelial dysfunction and hormonal imbalances. A randomized trial of 110 obese men (BMI ≥30 kg/m²) demonstrated that achieving a 10% or greater reduction in body weight through caloric restriction and increased physical activity led to significant improvements in International Index of Erectile Function (IIEF) scores, with 31% of participants regaining normal erectile function compared to 5.5% in the control group receiving general advice. Smaller reductions of 5-10% body weight have also been associated with enhanced erectile function in clinical trials involving men with metabolic syndrome.^[50]^[51] Regular aerobic exercise further supports erectile health by improving cardiovascular fitness and endothelial function. Guidelines recommend at least 150 minutes of moderate-intensity aerobic activity per week, such as brisk walking or cycling, which has been shown to reduce ED risk and improve IIEF scores in men with comorbidities like hypertension or obesity. A systematic review of intervention studies confirmed that 160 minutes per week of supervised aerobic exercise for 6 months resulted in 14-86% relative improvements in erectile function across diverse populations.^[51]^[52] Smoking cessation is essential for preserving vascular integrity, as tobacco use doubles the risk of ED through endothelial damage and reduced penile blood flow. Quitting smoking leads to measurable improvements in erectile function, with one study of 181 men aged 30-60 showing significant IIEF score increases across all domains 6 months post-cessation, particularly in those with moderate to severe ED at baseline. Early benefits to vascular health emerge rapidly, with up to 25% of former smokers experiencing enhanced erectile function within the first year.^[53]^[54] Dietary patterns also influence ED prevention by mitigating cardiovascular risks. Adherence to the Mediterranean diet, rich in fruits, vegetables, nuts, fish, and olive oil, is inversely associated with ED incidence; a large cohort study of over 21,000 men found that higher Mediterranean diet scores correlated with a 22% lower risk of ED in those under 60 years old. Limiting alcohol intake to moderate levels (up to 14 standard drinks per week for men) helps avoid alcohol-induced vascular and neurological impairments that can exacerbate ED.^[55]^[56]^[57] Preventive strategies emphasize early management of comorbidities like hypertension, which shares pathophysiological pathways with ED. Controlling blood pressure through lifestyle measures reduces ED progression by protecting vascular health. Stress reduction techniques, such as mindfulness-based practices, address psychological contributors like performance anxiety; a scoping review of studies involving over 3,700 men reported improvements in erectile function and sexual satisfaction following mindfulness interventions.^[51]^[58] Psychological counseling, particularly cognitive-behavioral therapy (CBT), targets performance anxiety and related psychogenic factors amenable to change. Systematic reviews of randomized trials show that CBT, whether alone or combined with other approaches, significantly enhances erectile function and sexual satisfaction in men with psychogenic ED, with notable improvements observed in up to 70% of participants after 3-6 months. Success rates vary but often exceed 60% in addressing anxiety-driven dysfunction.^[59]

Pharmacological Treatments

Pharmacological treatments for erectile dysfunction primarily involve oral medications that enhance erectile function through targeted physiological pathways, with phosphodiesterase type 5 (PDE5) inhibitors serving as the first-line therapy due to their efficacy and safety profile.^[60] These agents inhibit the PDE5 enzyme, which normally degrades cyclic guanosine monophosphate (cGMP) in the smooth muscle cells of the corpus cavernosum, thereby amplifying the nitric oxide (NO)-cGMP signaling pathway to promote vasodilation and penile erection.^[61] Sildenafil (Viagra), the prototypical PDE5 inhibitor, is administered orally at doses of 25-100 mg approximately one hour before sexual activity and demonstrates efficacy in achieving successful intercourse in about 70% of men with mild to moderate erectile dysfunction.^[60] Tadalafil (Cialis), another widely used PDE5 inhibitor, offers dosing flexibility with 5-20 mg on-demand or low-dose daily regimens of 2.5-5 mg, providing up to 36 hours of efficacy and improved spontaneity compared to shorter-acting options.^[61] For patients unresponsive to oral PDE5 inhibitors or those preferring non-oral routes, intraurethral alprostadil (e.g., MUSE) represents an alternative prostaglandin E1 formulation that is absorbed through the urethral mucosa to directly relax cavernosal smooth muscle and increase blood flow.^[62] This therapy achieves adequate erections for intercourse in approximately 30-40% of users, though absorption rates are lower than with intracavernosal injection, leading to variable response.^[63] Common side effects include penile pain (up to 30%) and urethral burning (up to 6%), with the risk of priapism remaining low at less than 1%.^[64] In men with confirmed hypogonadism, where low testosterone levels contribute to erectile dysfunction often alongside vascular pathology, hormone replacement therapy with testosterone can improve overall sexual function.^[65] Administered via transdermal gels, patches, or intramuscular injections, testosterone supplementation enhances libido and erectile quality in hypogonadal individuals, with studies reporting symptomatic improvements in up to 40-60% of cases when baseline levels are low.^[66] This approach is particularly beneficial for those with treatment-resistant erectile dysfunction, as it addresses underlying endocrine deficits.^[67] Combination therapies, such as PDE5 inhibitors paired with testosterone replacement, are recommended for hypogonadal men who do not respond adequately to monotherapy, yielding synergistic improvements in erectile function by concurrently targeting vascular and hormonal mechanisms.^[68] Off-label use of low-dose daily tadalafil (e.g., 5 mg) has also gained popularity for its convenience in maintaining endothelial health and providing consistent efficacy without timing constraints.^[69] Across these pharmacological options, patient selection based on etiology ensures optimal outcomes while minimizing risks like headache, flushing, or cardiovascular concerns with PDE5 inhibitors.^[70]

Non-Pharmacological and Surgical Options

Non-pharmacological and surgical options provide alternatives for managing erectile dysfunction (ED), particularly in cases refractory to pharmacological treatments. These approaches encompass mechanical devices, regenerative therapies, and invasive procedures aimed at restoring erectile function through physical, vascular, or structural means. While they offer viable solutions for diverse etiologies of ED, including vascular, neurogenic, and severe organic causes, their selection depends on patient preferences, comorbidities, and disease severity. Vacuum erection devices (VEDs), also known as penis pumps, utilize negative pressure to draw blood into the penis, creating an erection that is maintained by a constriction ring placed at the base.^[71] To use a VED, the cylinder is placed over the flaccid penis, a vacuum is generated manually or electrically to induce tumescence, and the ring is applied for up to 30 minutes to prevent venous outflow during intercourse.^[71] Efficacy rates for achieving satisfactory erections range from 70% to 90%, with higher success in milder cases and post-prostatectomy rehabilitation.^[72] Long-term studies indicate that 8-16% of users may regain spontaneous erections with consistent application.^[73] Low-intensity extracorporeal shockwave therapy (Li-ESWT) delivers focused acoustic waves to the penile tissue, promoting angiogenesis, improving endothelial function, and enhancing nitric oxide signaling to support vascular repair.^[74] Typically administered in 6-12 sessions over several weeks, Li-ESWT is most effective for mild to moderate vasculogenic ED, with meta-analyses of trials from 2020-2025 reporting approximately 50% improvement in International Index of Erectile Function (IIEF) scores and reduced reliance on phosphodiesterase-5 inhibitors.^[75] Durability of benefits persists for up to 2 years in responsive patients, though optimal protocols remain under refinement. As of 2025, regulatory bodies continue to evaluate Li-ESWT for standardized approval.^[76]^[77] Penile implants represent a surgical intervention for severe or refractory ED, involving the placement of prostheses to enable on-demand rigidity. Inflatable penile prostheses (IPPs), consisting of cylinders, a pump, and a reservoir, allow concealment and natural flaccid states, whereas malleable (semirigid) rods provide constant firmness with manual positioning for simplicity.^[78] Surgical outcomes demonstrate high patient and partner satisfaction rates of around 90%, with IPPs often preferred for cosmetic and functional advantages over malleable devices.^[79] Complications occur in 2-11% of cases, including infections (1-3%), mechanical failure, and erosion, with antibiotic-coated implants reducing infection risks.^[80] Vibratory stimulation devices offer non-invasive external aids, particularly for neurogenic ED stemming from spinal cord injury or neuropathy, by applying targeted vibrations to the penile shaft or glans to elicit reflex erections via somatosensory nerve activation.^[81] Devices like the Viberect deliver dual vibrations at frequencies of 60-120 Hz, achieving erections suitable for intercourse in up to 80% of users with intact sacral reflexes.^[82] These aids are portable, FDA-approved for ED, and complement other therapies without systemic effects.^[81] Experimental therapies, including stem cell and gene-based approaches, target underlying pathophysiological deficits in ED. Stem cell therapy, using autologous mesenchymal stem cells (e.g., bone marrow- or adipose-derived) injected intracavernosally, aims to regenerate endothelial cells and smooth muscle. Phase II trials, such as NCT04594850, are ongoing as of 2025 to evaluate safety and efficacy in post-prostatectomy and diabetic patients, with preliminary preclinical data showing promise.^[83] Gene therapy, focusing on enhancing nitric oxide pathways (e.g., via plasmid delivery of endothelial NO synthase), shows promise in preclinical animal models for boosting vasodilation, but human trials are still in early phases as of 2025, with long-term safety data pending.^[84] These modalities hold promise for curative potential but require further randomized controlled trials to establish standardized protocols. While stem cell and gene approaches remain investigational, regenerative therapies like Li-ESWT are gaining traction for potential future approvals.^[77]

History and Society

Historical Perspectives

Ancient civilizations recognized erectile dysfunction, then termed impotence, as a medical concern and proposed various remedies rooted in empirical observation and mythology. The Ebers Papyrus, dating to approximately 1550 BCE, documents treatments for impotence among ancient Egyptians, including suppositories and ointments made from herbs, honey, and animal products to restore virility.^[85] Greek and Roman physicians, influenced by Hippocratic and Galenic traditions, prescribed herbal remedies such as satyrion root, rocket seeds, and pine nuts, believed to enhance potency through aphrodisiac properties, often applied topically or ingested to stimulate blood flow and desire.^[86] These approaches reflected early understandings of sexual health as intertwined with overall vitality, though lacking anatomical precision. From the medieval period through the 19th century, humoral theory dominated explanations of impotence, positing it as an imbalance of bodily fluids—blood, phlegm, yellow bile, and black bile—often linked to excess cold or moisture in the reproductive organs. Physicians like Avicenna in his Canon of Medicine (11th century) recommended dietary adjustments, purgatives, and warm herbal concoctions to restore humoral equilibrium and penile function.^[87] By the late 19th century, surgical interventions emerged; at the turn of the 20th century, early surgical interventions included penile venous ligation, first proposed by P.G. Wooten in 1902 for atonic impotence, marking an early shift toward anatomical corrections despite limited success and high risks.^[88] The 20th century brought transformative milestones in erectile dysfunction management, beginning with pharmacological innovations. In 1982, French urologist Ronald Virag discovered the efficacy of intracavernosal papaverine injections during a surgical procedure, enabling vasodilation and erection; this led to the development of self-injection therapies as a primary treatment option for vasculogenic and neurogenic causes.^[89] The approval of sildenafil (Viagra) by the U.S. Food and Drug Administration in March 1998 revolutionized care, offering the first effective oral phosphodiesterase-5 inhibitor that enhanced nitric oxide-mediated penile blood flow, dramatically increasing accessibility and reducing stigma for millions worldwide.^[90] In the post-2000 era, research emphasized the role of comorbidities in erectile dysfunction pathogenesis, recognizing strong associations with cardiovascular disease, diabetes, hypertension, and metabolic syndrome, which affect up to 40-70% of cases and necessitate integrated cardiovascular risk management.^[91] The 2020s have seen promising advancements in regenerative medicine, particularly stem cell therapies using adipose-derived or bone marrow mesenchymal stem cells to repair cavernosal tissue, improve endothelial function, and restore erectile capacity in preclinical and early clinical trials, offering potential cures for refractory cases beyond symptomatic relief. As of 2025, systematic reviews of clinical trials indicate stem cell therapy is safe with short-term improvements in erectile function, though long-term efficacy requires further validation.^[77]^[92] Erectile dysfunction (ED) is often shrouded in stigma, particularly tied to societal norms of masculinity that equate sexual performance with male identity and virility. This cultural perception leads to significant underreporting, as many men view ED as a personal failure or embarrassment, deterring them from seeking medical help. Global surveys indicate that while ED affects approximately 50% of men aged 40 to 70, a substantial portion—up to 75% in some studies—remain untreated due to these psychosocial barriers, exacerbating the condition's impact on mental health and relationships.^[93]^[94] In anthropological contexts, ED in tribal and indigenous societies is frequently attributed to spiritual or supernatural causes rather than physiological ones, reflecting holistic views of health intertwined with cosmology and community harmony. For instance, among the Basoga people of Uganda, impotence (known as obufiirwa) is often linked to witchcraft (bulogo), evil spirits (ebiteega), ancestral curses (obulame), or violations of taboos, such as neglecting clan rituals. Healing rituals typically involve herbal preparations, animal sacrifices, and cleansing ceremonies performed by diviners (baswezi) at shrines (amasabo), aiming to restore spiritual balance; common remedies include baths with herbs like omulondo root or appeasement offerings to deities associated with fertility. Similarly, in certain South American indigenous groups, such as those in the Amazon region, ED is treated through rituals combining bark infusions (e.g., mixed with aguardiente for daily consumption) and ceremonial invocations to address perceived spiritual imbalances. These practices underscore ED's role not just as a bodily ailment but as a disruption in social and cosmic order, often requiring communal participation.^[95] The terminology surrounding ED has evolved to mitigate stigma, originating from the Latin impotentia coeundi, meaning "lack of power" in coitus, which historically connoted broader inadequacy. This term, used for centuries, carried pejorative implications that discouraged open discourse. In 1992, the National Institutes of Health (NIH) Consensus Development Conference recommended replacing "impotence" with "erectile dysfunction" to emphasize its specific physiological nature, reduce embarrassment, and promote patient-provider communication, thereby addressing underdiagnosis. This shift marked a pivotal destigmatization effort, aligning medical language with a more neutral, treatable condition rather than personal deficiency.^[96]^[97] In modern society, media portrayals of ED have transitioned from taboo to mainstream through direct-to-consumer advertising, exemplified by Viagra (sildenafil) campaigns launched in 1998, which normalized discussions by depicting relatable scenarios of aging men regaining vitality. These ads, often featuring lifestyle imagery like romantic evenings, have increased awareness and treatment-seeking but also reinforced heteronormative narratives, sometimes overlooking diverse experiences. Access disparities persist, particularly in low-income regions, where limited healthcare infrastructure and high costs result in poor treatment coverage despite rising prevalence; for example, in sub-Saharan Africa, ED management is hindered by non-adherence and reliance on unregulated traditional remedies. Within LGBTQ+ communities, ED presents unique challenges, with gay and bisexual men reporting higher rates (up to 43% experiencing erection problems) due to factors like performance anxiety in non-penetrative contexts, minority stress, and compounded stigma in spaces emphasizing sexual prowess. Culturally sensitive approaches, including inclusive counseling, are essential to address these barriers without assuming heterosexual frameworks.^[98]^[99]^[100]

References

[1]
Erectile dysfunction - Symptoms and causes - Mayo Clinic
Mar 1, 2025 · Erectile dysfunction means not being able to get and keep an erection firm enough for sexual activity. It also is called impotence.Erectile dysfunction FAQs · Diagnosis and treatment · Dietary supplements for...Missing: prevalence | Show results with:prevalence
[2]
Erectile Dysfunction - StatPearls - NCBI Bookshelf - NIH
Erectile dysfunction (ED) is a prevalent and multifaceted condition that predominantly afflicts males beyond 40 years, with its prevalence escalating globally.
[3]
Erectile Dysfunction | Johns Hopkins Medicine
For 2025, the prevalence of ED is predicted to be approximately 322 million worldwide. In the past, erectile dysfunction was commonly believed to be caused by ...
[4]
Erectile dysfunction - Diagnosis and treatment - Mayo Clinic
Mar 1, 2025 · Lose excess weight. Being overweight can cause erectile dysfunction or make it worse. Be more physically active. Exercise can help with ...Symptoms and causes · Viagra and other oral... · Doctors and departmentsMissing: prevalence | Show results with:prevalence
[5]
Erectile Disorder DSM-5 302.72 (F52.21) - Theravive Counseling
Erectile Disorder is characterized by a recurrent inability to achieve or maintain an adequate erection during partnered sexual activities.
[6]
Male erectile dysfunction - ICD-11 MMS - Find-A-Code
Male erectile dysfunction is characterised by inability or marked reduction in the ability in men to attain or sustain a penile erection of sufficient duration ...Missing: definition | Show results with:definition
[7]
8 common erectile dysfunction myths - Mayo Clinic Health System
Jun 2, 2022 · Fact: It's normal to have difficulty maintaining an erection occasionally. It happens to most men and is perfectly normal. Talk with your ...
[8]
Priapism - StatPearls - NCBI Bookshelf - NIH
Sep 14, 2025 · Priapism is a disorder in which the penis maintains a prolonged, rigid erection in the absence of appropriate stimulation.Etiology · Epidemiology · Pathophysiology · Treatment / Management
[9]
Peyronie's disease - Symptoms and causes - Mayo Clinic
Aug 6, 2025 · Peyronie's disease might cause problems getting or keeping an erection. This also is called erectile dysfunction. Often though, people with ...Diagnosis and treatment · Penile traction therapy · Plication of the penisMissing: priapism | Show results with:priapism
[10]
results of the Massachusetts Male Aging Study - PubMed
The combined prevalence of minimal, moderate and complete impotence was 52%. The prevalence of complete impotence tripled from 5 to 15% between subject ages 40 ...
[11]
[PDF] The global prevalence of Erectile Dysfunction: a review
It is estimated that 322 million men worldwide will be affected by ED by 2025, an increase from 152 million men in 19951. This is also reflected by a growing ...<|separator|>
[12]
The global prevalence of erectile dysfunction: a review - PubMed
The global prevalence of ED was 3-76.5%. ED was associated with increasing age. Use of the International Index of Erectile Function (IIEF) and Massachusetts ...
[13]
Prevalence and determinants of erectile dysfunction among type 2 ...
In conclusion, the prevalence of erectile dysfunction among adult T2DM is nearly eight out of ten. ED health-seeking behavior was poor, with only a minority of ...
[14]
Relationship Between Age, Comorbidity, and the Prevalence of ...
Our study shows how the probability of erectile dysfunction (ED) changes with increasing age, analyzed alone and when taking into account the presence of other ...
[15]
Relationship Between Age, Comorbidity, and the Prevalence of ...
Aug 26, 2022 · Our study shows how the probability of erectile dysfunction (ED) changes with increasing age, analyzed alone and when taking into account the presence of other ...
[16]
Association of Erectile Dysfunction With Cardiovascular Risk Factors ...
Aug 1, 2005 · The Massachusetts Male Aging Study emphasized the close relationship between diabetes and ED, which was three times more prevalent in diabetic ...
[17]
A Prospective Study of Risk Factors for Erectile Dysfunction
We found that obesity and smoking were positively associated, and physical activity was inversely associated with the risk of erectile dysfunction developing.
[18]
Erectile Dysfunction as an Independent Predictor of Future ...
Vascular erectile dysfunction (ED) and cardiovascular disease (CVD) share common risk factors including obesity, hypertension, metabolic syndrome, diabetes ...<|separator|>
[19]
1 in 5 men surveyed had erectile dysfunction up to 2 years after COVID
Mar 6, 2025 · A total of 19.0% of 609 men who completed a survey in Japan and had persistent COVID symptoms reported erectile dysfunction (ED) 1 and/or 2 years post- ...
[20]
Effect of COVID‐19 infection on the erectile function - PMC
... erectile dysfunction (ED). In many cases, more than one pathophysiological ... mental health further deteriorates and symptoms of post‐traumatic stress disorder ...
[21]
https://pmc.ncbi.nlm.nih.gov/articles/PMC9874733/
[22]
All about Peyronie's disease - PMC - NIH
Men may suffer from penile pain, deformities and erectile dysfunction ... pain but not penile curvature or penile plaque size [40]. In a more recent ...
[23]
The use of the simplified International Index of Erectile Function (IIEF ...
The possible scores for the IIEF-5 range from 5 to 25, and ED was classified into five categories based on the scores: severe (5-7), moderate (8-11), mild to ...
[24]
Factors associated with anxiety and depression in patients with ...
Feb 4, 2023 · The prevalence of anxiety and depression among ED patients was 38.16% and 64.97%, respectively. The mean anxiety index score was 47.37 ± 6.69 ...
[25]
The Psychology of Erectile Dysfunction - Mark S. Allen, Alex M ...
Sep 8, 2023 · If erectile problems do not cause any distress, then the person would not be considered to be experiencing erectile dysfunction according to ...Missing: post- | Show results with:post-
[26]
Psychological consequences of erectile dysfunction - Sheng - 2021
Nov 24, 2021 · Erectile dysfunction is one of the most common sexual disorders, and its effect on the individual and their relationships can be significant.
[27]
Erectile dysfunction in patients with anxiety disorders - Nature
Feb 18, 2021 · Psychiatric illness has been associated with sexual dysfunctions in both men and women, this could be through the mental health disorder itself ...
[28]
A Psychosocial Approach to Erectile Dysfunction - PubMed Central
Oct 7, 2021 · Although erectile dysfunction (ED) involves an interaction between physiological and psychological pathways, the psychosocial aspects of ED have ...
[29]
Can lifestyle modification affect men's erectile function? - PMC
In another large-scale study, greater degree of sedentary behavior was strongly associated with ED after multivariable adjustment. Men who spent ≥5 h per day ...
[30]
Short Sleep Duration and Erectile Dysfunction - PubMed Central - NIH
Oct 27, 2022 · A growing body of research has revealed a possible link between sleep disorders and erectile dysfunction (ED).
[31]
Associations Between Online Pornography Consumption and ...
The aim of this study was to better understand associations between problematic pornography consumption (PPC) and ED.Missing: overuse | Show results with:overuse
[32]
Physiology, Erection - StatPearls - NCBI Bookshelf
The physiology of an erection can break down into arterial dilation and venous occlusion. In most cases, tumescence occurs following sexual stimulation. This ...Missing: physical | Show results with:physical
[33]
Physiology of Penile Erection and Pathophysiology of Erectile ...
Because an erection is a neurovascular event, any disease or dysfunction affecting the brain, spinal cord, cavernous and pudendal nerves can induce dysfunction.
[34]
Relationship Between Testosterone and Erectile Dysfunction - PMC
Normal adult testosterone levels are not necessary for normal erections. There is a gradual decline with age of total and free testosterone levels in healthy ...
[35]
Anatomy, Pathophysiology, Molecular Mechanisms, and Clinical ...
Apr 16, 2021 · This review will summarize the mechanism of men's erection, focusing on pathophysiology and molecular mechanisms of erectile dysfunction, with a ...
[36]
The Role of Nitric Oxide in Erectile Dysfunction - PubMed Central - NIH
Nitric oxide (NO) is believed to be the main vasoactive nonadrenergic, noncholinergic neurotransmitter and chemical mediator of penile erection.
[37]
Neurogenic Erectile Dysfunction. Where Do We Stand? - PMC
Jan 7, 2021 · Neurogenic Sexual dysfunction (NSD) has a prevalence of between 10% and 19% of all causes of erectile dysfunction (ED) [3].3.1. Central Nervous System... · 3.1. 1. Spinal Cord Injury... · 5.2. Local Therapies
[38]
Erectile Dysfunction in Individuals with Neurologic Disability
Several medical conditions, beyond aging perse, are associated with erectile dysfunction (ED). ... Neurologic ED can be broadly defined as an inability to sustain ...
[39]
Oxidative Stress and Erectile Dysfunction: Pathophysiology, Impacts ...
This narrative review aims to elucidate the role of OS in the pathophysiology of ED, focusing on impact, mechanisms, and potential therapeutic interventions.
[40]
Reversion of penile fibrosis: Current information and a new horizon
The aim of the current review is to shed some light on the underlying aetiology of corporal fibrosis especially ageing, cavernous nerve damage, androgen ...
[41]
Testosterone and Erectile Function: From Basic Research to a New ...
Testosterone levels in the range of 10% of the normal physiologic plasma concentration may represent a threshold value, below which erectile function declines ...
[42]
Aging and androgens: Physiology and clinical implications - PMC
Aging-related changes in testosterone metabolism and androgen sensitivity associated with aging in men. There is a decline in testosterone production that is ...
[43]
Erectile Dysfunction: AUA Guideline - Journal of Urology
Sep 1, 2018 · The purpose of this guideline is to provide a clinical strategy for the diagnosis and treatment of erectile dysfunction.
[44]
MANAGEMENT OF ERECTILE DYSFUNCTION - Uroweb
Erectile dysfunction is defined as the persistent inability to attain and maintain an erection sufficient to permit satisfactory sexual performance [245].
[45]
MRI of the penis - PMC - NIH
Erectile dysfunction. Peyronie's disease and penile fibrosis can both cause erectile dysfunction and can be imaged on MRI. However, clinical tests of ...
[46]
Effect of Lifestyle Changes on Erectile Dysfunction in Obese Men
This study provides evidence that weight loss achieved by lifestyle changes can ameliorate erectile function in obese men with erectile dysfunction at baseline.
[47]
Lifestyle modifications and erectile dysfunction: what can be ...
Sep 9, 2014 · Lifestyle modifications were effective in ameliorating ED or restoring absent ED in people with obesity or metabolic syndrome.
[48]
Physical Activity to Improve Erectile Function: A Systematic Review ...
Apr 13, 2018 · Overall, weekly exercise of 160 minutes for 6 months contributes to decreasing erectile problems in men with ED caused by physical ...
[49]
Modifying Risk Factors in the Management of Erectile Dysfunction
Aug 23, 2016 · The literature suggests that smoking cessation, treatment of hyperlipidemia, and increasing physical activity will improve erectile function in many patients.
[50]
Effect of smoking cessation on sexual functions in men aged 30 to ...
Erectile function is directly proportional to the degree of exposure to smoking, and quitting smoking improves male sexual function in all age groups between 30 ...
[51]
Diet and Erectile Dysfunction Among Men in the Health ...
Nov 13, 2020 · Higher Mediterranean diet scores were also inversely associated with incident erectile dysfunction among older men (age 60 to <70 years: HR, ...
[52]
A Meta-Analysis of Erectile Dysfunction and Alcohol Consumption
The results of our meta-analysis indicated that there was a significant association between regular alcohol consumption and ED (OR 0.89, 95% confidence interval ...Missing: limit | Show results with:limit
[53]
A Scoping Review of the Influence of Mindfulness on Men's Sexual ...
Studies related to male sexual dysfunction have focused on the effect of mindfulness on reducing performance anxiety, thought fusion, and sexual desire, with ...
[54]
The effectiveness of psychological interventions alone, or in ... - NIH
Significant improvement in erectile function and sexual satisfaction was found in all three groups after 3 months. Furthermore, combined treatment and ...
[55]
Phosphodiesterase-5 (PDE5) Inhibitors In the Management of ... - NIH
Sildenafil, vardenafil, tadalafil, and avanafil are classified as PDE5 inhibitors and are indicated for the treatment of men with ED. Sildenafil, the first PDE5 ...
[56]
PDE5 Inhibitors - StatPearls - NCBI Bookshelf - NIH
Sildenafil: 25 mg to 100 mg orally administered 1 hour before intercourse · Tadalafil: 5 mg to 20 mg orally administered 1 hour before intercourse · Vardenafil: ...
[57]
Alprostadil - StatPearls - NCBI Bookshelf
Feb 6, 2025 · Common adverse effects include hypotension, flushing, and priapism, which require immediate intervention if prolonged. This activity reviews the ...
[58]
Erectile dysfunction - PubMed
Transurethral alprostadil is significantly less effective than alprostadil ICI, producing improved erections in 30%-40%, but rigid erections in only 10%, of men ...
[59]
[PDF] MUSE® (alprostadil) urethral suppository - accessdata.fda.gov
The most common side effects of MUSE include: • Pain in the penis, urethra, or testicles. Warmth or burning sensation in the urethra. Redness of the penis.
[60]
Testosterone Replacement Therapy: A Narrative Review with a ...
Positive impacts of TRT on hypogonadism include improvements in erectile dysfunction, libido, lean body mass and bone mineral density.
[61]
Testosterone Therapy Improves Erectile Function and Libido in ... - NIH
Testosterone therapy has also shown consistent benefit in improving libido in men with low testosterone levels at baseline, with no additional improvements once ...<|control11|><|separator|>
[62]
Management of Erectile Dysfunction in the Hypogonadal Man
In a study of TST with gels or patches (N = 227), hypogonadal men reported improvements in sexual motivation, desire, and enjoyment with a partner, and ...
[63]
Synergetic effect of testosterone and phophodiesterase-5 inhibitors ...
Testosterone deficiency seems to impair the clinical response to phophodiesterase-5 (PDE-5) inhibitors in patients with erectile dysfunction (ED).
[64]
A once-daily dose of tadalafil for erectile dysfunction - PubMed Central
As an on-demand treatment, PDE5Is have excellent efficacy and safety in the treatment of ED due to a broad spectrum of etiologies. Nevertheless, these drugs do ...
[65]
Phosphodiesterase type 5 inhibitors as a treatment for erectile ... - NIH
Sep 18, 2013 · Each PDE5 inhibitor has an excellent and comparable efficacy and tolerability. These drugs are highly effective for ED of various causes.<|control11|><|separator|>
[66]
Penis pump - Mayo Clinic
Using a penis pump won't cure erectile dysfunction. But it might create an erection firm enough for sex. You might need to use a penis pump along with other ...Missing: success rate
[67]
recommendations from the 5th international consultation on sexual ...
In reviewing published outcomes, VED consistently demonstrates high efficacy rates for achieving an erection in most populations, including 70%–82% in DM, 70%– ...
[68]
Long-Term Results with Vacuum Constriction Device - ScienceDirect
A minority of patients (8–16%) reported on the return of spontaneous erections with the long-term use of VED [174,175,178,180]. In conclusions on VED, among all ...
[69]
Efficacy of low-intensity extracorporeal shock wave therapy for ...
Jun 11, 2025 · Low-intensity extracorporeal shockwave therapy (Li-ESWT) is proposed for the treatment of erectile dysfunction (ED).
[70]
(PDF) Efficacy of low-intensity extracorporeal shock wave therapy for ...
Aug 7, 2025 · Taken together, these results suggest that the Li-ESWT may hold promise for patients with ED. Key Words: Erectile dysfunction, Low-intensity ...
[71]
Is low-intensity shockwave therapy for erectile dysfunction a durable ...
Oct 31, 2024 · Erectile dysfunction (ED) is an increasingly prevalent disorder with increased age and presence of comorbid conditions (1). As the predominant ...
[72]
Penile implants - Mayo Clinic
Jan 19, 2024 · Inflatable penile implants are also available with antibiotic coatings, which might help reduce the risk of infection, and coatings to reduce ...
[73]
Safety and Efficacy of Inflatable Penile Prostheses for the Treatment ...
Feb 10, 2022 · With its high overall satisfaction rates and low risk of complications, the inflatable penile prosthesis remains an excellent option for patients with erectile ...
[74]
Recent technological development of penile prosthesis: a literature ...
In a review paper in 2018 on two-piece IPPs, overall complication rates were between 2.1% to 11.2% while infection rates ranged from 0.7% to 4.8%, and ...<|separator|>
[75]
New advances in erectile technology - PMC - PubMed Central
Viberect, developed by Reflexonic, Chambersburg, Pennsylvania, is an FDA approved class II medical device used to provoke penile erection in men with ED and to ...
[76]
Genital vibration for sexual function and enhancement: a review of ...
The literature indicates that vibratory stimulation has evidence-based support for the treatment of erectile dysfunction, ejaculatory dysfunction and anorgasmia ...
[77]
https://www.frontiersin.org/journals/medicine/articles/10.3389/fmed.2025.1519095/full
[78]
Gene Therapy in Erectile Dysfunction: Dead or Alive? - ResearchGate
Aug 7, 2025 · Current gene-based strategies for treatment of erectile dysfunction (ED) are based on the nitric oxide (NO)/cGMP system; although growth factors ...<|control11|><|separator|>
[79]
Erectile Dysfunction: A Review of Historical Treatments With a Focus ...
Jul 23, 2015 · Erectile dysfunction (ED) is defined as the persistent inability to achieve or maintain an erection sufficient for satisfactory sexual ...Missing: herbal | Show results with:herbal
[80]
Erectogenic Drugs in Greek Medicine
Feb 13, 2019 · As for the latter, the phraseology of sexual inability did not necessarily refer to men with what is labeled today as erectile dysfunction. The ...
[81]
Physiology of Penile Erection—A Brief History of the Scientific ... - NIH
Oct 22, 2015 · ... erectile dysfunction [3]: The erection of the human penis occurs through three mechanisms: 1. Imagination, 2 moisture, which increases in ...
[82]
Erectile Dysfunction Caused by Cavernous Leakage - IntechOpen
At the turn of the twentieth century, the first results of penile venous ligation were published. Simple isolated ligation of the deep dorsal vein in humans for ...
[83]
Intracavernous injection of papaverine for erectile failure. 1982
Intracavernous injection of papaverine for erectile failure. 1982. ... Erectile Dysfunction / history*; History, 20th Century; Humans; Male; Papaverine ...Missing: discovery | Show results with:discovery
[84]
Sildenafil: from angina to erectile dysfunction to pulmonary ...
The FDA approved Viagra for the treatment of men with ED in March 1998. European approval followed in September 1998. The introduction of Viagra to the market ...
[85]
Prevalence, Comorbidities, and Risk Factors of Erectile Dysfunction
Mar 20, 2022 · Previous epidemiological research has reported that among men with ED, approximately 40% have hypertension; 42% have hyperlipidemia; and 20% ...
[86]
Advances in stem cell therapy for erectile dysfunction - Frontiers
Apr 1, 2025 · In this trial, increases in sexual pleasure and erectile function were more pronounced at the 6-month mark and persisted for a year (35, 36).
[87]
[PDF] ERECTILE DYSFUNCTION:THE MALE STIGMA - ejos.org
The cases of ED are often underreported due to the stigma at- tached to it. However, recent advancement in the diagnosis and therapy has enabled a large ...
[88]
Majority of Men Do Not Treat Their Erectile Dysfunction - PR Newswire
Of the more than 6.2 million ED patients examined, 25.4 percent were treated and 74.6 percent went untreated. The most commonly prescribed medications were ...
[89]
[PDF] a study of religion, culture, and medicinal plants of three south ...
Erection. Medicine. (Huini=Erection,. Rao=Medicine). When a man has erectile dysfunction, he must mix the bark with aguardiente and drink it every morning ...
[90]
Impotence in the 18th and 19th century: concepts of etiology and ...
Historically, the pharmacological treatments for impotence started in Greek times, when a myriad of herbal medications were applied locally to the genitals ...
[91]
Impotence - PubMed - NIH
Among their findings, the panel concluded that (1) the term "erectile dysfunction" should replace the term "impotence"; (2) the likelihood of erectile ...
[92]
Viagra's contribution to pharmaceutical fetishism and patient-as ...
Viagra's advertising evolution. Erectile dysfunction (ED) can affect men under the age of 40, but occurs at higher rates for aging populations, with rates ...
[93]
Erectile dysfunction among diabetic patients in Western Uganda
Oct 23, 2025 · The prevalence is soaring in low-income and middle-income countries seems higher while are burdened with poor treatment coverage [3,4,5]. In ...
[94]
The Impact of Sexual Orientation on Sexuality and Sexual Practices ...
... erectile dysfunction and ejaculatory problems. Problems with erection over the past 3 months were reported by 43% of gay men compared with 31% of ...